LPS-adsorber in patients with septic shock

S.P. Loginov1, E.G. Gromova2, M.V. Kiselevskij2, N.P. Krotenko1, Ju.I. Doljikova2, R.Ja. Vlasenko2, L.S. Kuznetsova2

1 Botkinskaia State Hospital, Moscow

2 Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation, Moscow

For correspondence: Gromova Elena Georgievna — MD, Head of the Intensive Care Unit № 2 FBSI “N.N. Blokhin NMRCO”, Moscow; e-mail: e_gromova05@mail.ru

For citation: Loginov SP, Gromova EG, Kiselevskij MV, Krotenko NP, Doljikova JuI, Vlasenko RJa, Kuznetsova LS. LPS-adsorber in patients with septic shock. Alexander Saltanov Intensive Care Herald. 2018;3:46–52.

DOI: 10.21320/1818-474X-2018-3-46-52


The results of lipopolysaccharide (LPS) sorption using selective LPS adsorber (Alteco) in 20 patients with gram-negative sepsis were investigated. From 2 to 6 hemoperfusion operations were performed. Concentrations of interleukins (IL): IL-6, IL-8, IL-10, IL-18, lipopolysaccharide (LPS) in serum before and after the procedure, and in washouts from sorbents were controlled. Decrease in LPS was accompanied by improvement or normalization of clinical and laboratory parameters, more pronounced in the group of survivors. High sorption capacity of LPS-adsorber and its efficiency in elimination of not only LPS but cytokine excess from the blood flow have been demonstrated.

Keywords: sepsis, septic shock, Alteco LPS adsorber, LPS, interleukins

Received: 07.08.2018


References

  1. Kaukonen K.M., Bailey M., Suzuki S., et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014; 311(13): 1308–1316.
  2. Анисимова Н.Ю., Громова Е.Г., Кузнецова Л.С. и др. Динамика элиминации бактериальных эндотоксинов и цитокинов из крови онкологических больных с сепсисом при гемосорбции с использованием угольных сорбентов. Бюллетень экспериментальной биологии и медицины. 2011; 151(5): 560–562. [Anisimova N.Yu., Gromova E.G., Kuznetsova L.S., et al. Dinamika eliminacii bakterialʼnyh endotoksinov i citokinov iz krovi onkologicheskih bolʼnyh s sepsisom pri gemosorbcii s ispolʼzovaniem ugolʼnyh sorbentov. Byulletenʼ eksperimentalʼnoj biologii i mediciny. 2011; 151(5): 560–562. (In Russ)]
  3. Анисимова Н.Ю., Киселевский М.В., Громова Е.Г., Кузнецова Л.С. Селективная и неселективная гемосорбция в интенсивной терапии онкологических больных с тяжелым сепсисом. Медицинский алфавит. 2011; 4(18): 29–33. [Anisimova N.Yu., Kiselevskij M.V., Gromova E.G., Kuznetsova L.S. Selektivnaya i neselektivnaya gemosorbciya v intensivnoj terapii onkologicheskih bolʼnyh s tyazhyolym sepsisom. Medicinskij alfavit. 2011; 4(18): 29–33. (In Russ)]
  4. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001; 29(7): 1303–1310.
  5. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit. Care Med. 2009; 37(1): 291–304.
  6. Kulabukhov V.V. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol. Scand. 2008; 52(7): 1024–1025.
  7. Ronco C., d’Intini V., Bellomo R., et al. Обоснование применения экстракорпоральных методов лечения при сепсисе. Анестезиология и реаниматология. 2005; 2: 87–91. [Ronco C., d’Intini V., Bellomo R., et al. Obosnovanie primeneniya ekstrakorporalʼnyh metodov lecheniya pri sepsise. Anesteziologiya i reanimatologiya. 2005; 2: 87–91. (In Russ)]
  8. Ярустовский М.Б., Абрамян М.В., Попок З.В., и др. Селективная гемоперфузия при грамотрицательном тяжелом сепсисе у больных после кардиохирургических операций: проспективное рандомизированное исследование. Анестезиология и реаниматология. 2010; 6: 60–65. [Yarustovskij M.B., Abramyan M.V., Popok Z.V., et al. Selektivnaya gemoperfuziya pri gramotricatelʼnom tyazhelom sepsise u bolʼnyh posle kardiohirurgicheskih operacij: prospektivnoe randomizirovannoe issledovanie. Anesteziologiya i reanimatologiya. 2010; 6: 60–65. (In Russ)]
  9. Yaroustovsky M., Abramyan M., Popok Z., et al. Preliminary Report regarding the Use of Selective Sorbents in Complex Cardiac Surgery Patients with Extensive Sepsis and Prolonged Intensive Care Stay. Blood Purif. 2009; 28(3): 227–233.
  10. Blomquist S., Gustafsson V., Manolopoulos T., Pierre L. Clinical experience with a novel endotoxin adsorbtion device in patients undergoing cardiac surgery. Perfusion. 2009; 24(1): 13–17.
  11. Ala-Kokko T.I., Laurila J., Koskenkari J. A New Endotoxin Adsorber in Septic Shock: Observational Case Series. Blood Purif. 2011; 32(4): 303–309.
  12. Shum H.P., Leung Y.W., Lam S.M., et al. Alteco endotoxin hemoadsorption in Gram-negative septic shock patients. Indian J. Crit. Care Med. 2014; 18(12): 783–788.
  13. Lipcsey M., Tenhunen J., Sjölin J., et al. Abdominal Septic Shock — Endotoxin Adsorption Treatment (ASSET) — endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial. Trials. 2016; 17(1): 587–597.
  14. Маевская М.В., Буеверов А.О. Цитокины в патогенезе алкогольного гепатита и возможности терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2009; 2: 14–19. [Maevskaya M.V., Bueverov A.O. Citokiny v patogeneze alkogolʼnogo gepatita i vozmozhnosti terapii. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2009; 2:14–19. (In Russ)]
  15. Zhou M., Cheng S., Yu J., Lu Q. Interleukin-8 for Diagnosis of Neonatal Sepsis: A Meta-Analysis. PLoS One. 2015; 10(5): e0127170.
  16. Колесниченко А.П., Мосякин Н.А., Распопин Ю.С., и др. Биомаркеры и эфферентные методы терапии тяжелого сепсиса. Вестник интенсивной терапии. 2015; 4: 11–15. [Kolesnichenko A.P., Mosyakin N.A., Raspopin Yu.S., et al. Biomarkyory i efferentnye metody terapii tyazhyologo sepsisa. Vestnik intensivnoj terapii. 2015; 4: 11–15. (In Russ)]
  17. Zhou F., Peng Z., Murugan R., Kellum J.A. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit. Care Med. 2013; 41(9): 2209–2220.
  18. Хорошилов С.Е., Карпун Н.А., Половников С.Г. и др. Селективная гемосорбция эндотоксина в лечении абдоминального сепсиса. Общая реаниматология. 2009; 5(6): 83. [Horoshilov S.E., Karpun N.A., Polovnikov S.G., et al. Selektivnaya gemosorbciya ehndotoksina v lechenii abdominal’nogo sepsisa. Obshchaya reanimatologiya. 2009; 5(6): 83. (In Russ)]
  19. Teichholz L.E., Kreulen Т., Herman M.V. et al. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am. J. Cardiol. 1976; 37(1): 7–11.
  20. Tuguz A.R., Kiselevsky M.V., Gromova E.G., Matveev V.B. Cytokines dynamics in the blood, urine and drainage liquid in the earlier postoperative period of kidney cancer patients. 18th UICC International Cancer Congress 30 June — 5 July, 2002. Oslo, Norway. P. 876.
  21. Surviving Sepsis Campaign. International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Critical Care Med. 2013; 41(2): 580–637.
  22. Тугуз А.Р. Иммунопатогенез ранних послеоперационных осложнений у онкологических больных. Дисс. … докт. мед. наук. М., 2002. [Tuguz A.R. Immunopatogenez rannih posleoperacionnyh oslozhnenij u onkologicheskih bolʼnyh. Diss. … dokt. med. nauk. M., 2002. (In Russ)]
  23. Anisimova N.Yu. Immunological Pathogenesis of Sepsis and Use of Hemosorption for Treatment of Cancer Patients With Sepsis. Nova Science Publishers Inc., 2014: 75–115.